Time to market for Tivozanib

Tivozanib, also known as FOTIVDA, is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma after failure of systemic therapy. It was approved by the U.S. Food and Drug Administration (FDA) on March 10, 2021. Tivozanib, marketed by Aveo Oncology, is a promising treatment for patients with RCC who have not been successfully treated with other therapies. Renal cell carcinoma accounts for 3% of cancer cases and is one of the 10 most common cancers in adults, with the average age at diagnosis being between 65 and 74 years old.

Tivozanib, a tyrosine kinase inhibitor, may target all vascular endothelial growth factor receptors (VEGFRs), thereby inhibiting angiogenesis. A major study showed that tivozanib increased the time it took for the disease to worsen by nearly three months compared with another approved drug, sorafenib. TivozanibThe most common side effects are considered manageable, although they may affect patients' quality of life. In general, its side effects are in line with expectations for similar drugs (VEGF inhibitors). Therefore, the European Medicines Agency (EMA) concluded that the benefits of tivozanib outweighed its risks and recommended in 2017 that it be authorized in the EU.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.